$8.86
+0.6650 ( +8.12% ) 4.2M
Clinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| Galinpepimut-SDetailsBlood cancer, Acute myeloid leukemia, Cancer | Phase 3 |
| SLS009 (GFH009) +/- venetoclax & azacitidineDetailsCancer, Blood cancer, Acute myeloid leukemia, Lymphoma | Phase 2a |
| SLS009 (GFH009)+BrukinsaDetailsCancer, Blood cancer, Diffuse large B cell lymphoma | Phase 1/2 |
| Galinpepimut-S + KEYTRUDA (pembrolizumab)DetailsOvarian cancer, Solid tumor/s, Cancer | Phase 1/2 |
| SLS009 (GFH009)DetailsBlood cancer, Cancer, Lymphoma, Peripheral T-cell Lymphomas | Phase 1/2 |
| SLS009 (GFH009)DetailsCancer, Blood cancer, Pediatric Sarcomas | Phase 1 |
| Galinpepimut-S + OPDIVO (nivolumab)DetailsCancer, Malignant pleural/peritoneal mesothelioma | Phase 1 |
| Nelipepimut-SDetailsSolid tumor/s, Cancer, Breast cancer, Triple-negative breast cancer | Failed |
| Galinpepimut-SDetailsBlood cancer, Cancer, Acute myeloid leukemia | Phase 3 |
| SLS009 (GFH009) +/- venetoclax & azacitidineDetailsBlood cancer, Cancer, Acute myeloid leukemia, Lymphoma | Phase 2a |
Market Data
| Open | $8.86 |
| Previous Close | $8.19 |
| Volume | 4.2M |
| Market Cap | $1.61B |
| Day Range | $7.90 - $9.00 |
| 52 Week Range | $1.39 - $9.51 |
| Shares Outstanding | 196.63M |
| Change % | +8.12% |
| Net Change | ▲ 0.6650 |
| Insider Ownership | -0.06% |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2008 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased: -261,398.00
| Date | Type | Amount Purchased | Purchaser |
|---|---|---|---|
| 2025-06-13 | Buy | 10000.00 | VAN NOSTRAND ROBERT L |
| 2025-06-02 | Buy | 20000.00 | Wasman Jane |
| 2025-05-22 | Buy | 20000.00 | Kalin Katherine Bach |
| 2024-01-25 | Sale | -6000.00 | SCHEINBERG DAVID A |
| 2024-01-25 | Sale | -6000.00 | Kalin Katherine Bach |
| 2024-01-25 | Sale | -6000.00 | Wasman Jane |
| 2024-01-25 | Sale | -20000.00 | Francomano Robert |
| 2024-01-25 | Sale | -6000.00 | Varian John |
| 2024-01-25 | Sale | -6000.00 | VAN NOSTRAND ROBERT L |
| 2024-01-25 | Sale | -47000.00 | Burns John Thomas |
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| schedule | Other | 2 | Nov 14, 2025 |
| 8-k | 8K-related | 13 | Nov 12, 2025 |
| 10-q | Quarterly Reports | 59 | Nov 12, 2025 |
| 8-k | 8K-related | 18 | Oct 27, 2025 |
| 8-k | 8K-related | 13 | Oct 03, 2025 |
| 8-k | 8K-related | 15 | Sep 11, 2025 |
| 10-q | Quarterly Reports | 60 | Aug 12, 2025 |
| 8-k | 8K-related | 13 | Aug 12, 2025 |
| 8-k | 8K-related | 12 | Jun 18, 2025 |
| 4 | Insider transactions | 1 | Jun 13, 2025 |
Latest News
Hello, I'm RedChat, your AI assistant for SLS